Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer’s Disease: in Search of a Relevant Mechanism

Molecular Neurobiology

Volumn 53, Issue 3, 2016, Pages 1741-1752

  Grieb, Paweł ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Brain; Insulin producing cells; Insulin receptors; Intracerebroventricular streptozotocin injection; Non transgenic Alzheimer s disease model

Indexed keywords

ALLOXAN; AMYLOID BETA PROTEIN; GLUCOSE TRANSPORTER 2; INSULIN RECEPTOR; STREPTOZOCIN; TAU PROTEIN; GLUCOSE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN METABOLISM; CELL DEATH; CIRCUMVENTRICULAR ORGAN; CYTOTOXICITY; DISEASE MODEL; DNA ALKYLATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HYPOTHALAMUS; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; KIDNEY; LIVER; MAMMAL; NERVE CELL DEGENERATION; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REVIEW; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; CHEMICALLY INDUCED; HUMAN; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; GLUCOSE; HUMANS; INJECTIONS, INTRAVENTRICULAR; RECEPTOR, INSULIN; STREPTOZOCIN;

EID: 84961145929     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9132-3     Document Type: Review

References (104)

1. Hau J (2008) Animal models of human diseases. In: Conn PM (ed) An overview. (in:) Sourcebook of Models for Biomedical Research, vol Chapt. 1. Humana Press, Totowa, pp 15–20
2. Bertram L, Tanzi RE (2012) The genetics of Alzheimer's disease. Prog Mol Biol Transl Sci 107:79–100
3. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523–527
4. Li C, Ebrahimi A, Schluesener H (2013) Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease. Ageing Res Rev 12:116–140
5. Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG et al (2011) Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther 3:28
6. Zahs KR, Ashe KH (2010) 'Too much good news'—are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci 33:381–389
7. Geerts H (2009) Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs 23:915–926
8. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184–185
9. Gilbert BJ (2013) The role of amyloid β in the pathogenesis of Alzheimer's disease. J Clin Pathol 66:362–366
10. Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H et al (2008) Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 29:676–692
11. Crews L, Rockenstein E, Masliah E (2010) APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct Funct 214:111–126
12. Armstrong RA (2013) What causes Alzheimer's disease? Folia Neuropathol 51:169–188
13. Mondragón-Rodríguez S, Basurto-Islas G, Lee HG, Perry G, Zhu X, Castellani RJ, Smith MA (2010) Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother 10:683–691
14. Skaper SD (2012) Alzheimer's disease and amyloid: culprit or coincidence? Int Rev Neurobiol 102:277–316
15. Swerdlow RH (2012) Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox Res 22:182–194
16. Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, Tsui W, Ginestroni A et al (2006) Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 47:1778–1786
17. Hoyer S, Nitsch R, Oesterreich K (1991) Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 3:1–14
18. Ogawa M, Fukuyama H, Ouchi Y, Yamauchi H, Kimura J (1996) Altered energy metabolism in Alzheimer's disease. J Neurol Sci 139:78–82
19. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, Konishi J (1994) Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med 35:1–6
20. Gabuzda D, Busciglio J, Chen L, Matsudaira P, Yankner B (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269:13623–13628
21. Grieb P, Gordon-Krajcer W, Frontczak-Baniewicz M, Walski M, Ryba MS, Kryczka T, Fiedorowicz M, Kulinowski P et al (2004) 2-deoxyglucose induces beta-APP overexpression, tau hyperphosphorylation and expansion of the trans-part of the Golgi complex in rat cerebral cortex. Acta Neurobiol Exp (Wars) 64:491–502
22. Velliquette RA, O'Connor T, Vassar R (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 25:10874–10883
23. Horton RW, Meldrum BS, Bachelard HS (1973) Enzymic and cerebral metabolic effects of 2-deoxy-D-glucose. J Neurochem 21:507–520
24. Myers N, Pasquini L, Göttler J, Grimmer T, Koch K, Ortner M, Neitzel J, Mühlau M et al (2014) Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer's disease. Brain 137:2052–2064
25. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, Morris JC, Raichle ME et al (2010) Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proc Natl Acad Sci U S A 107:17763–17767
26. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes? J Alzheimers Dis 7:63–80
27. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J et al (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 102:1106–1112
28. Junod A, Lambert AE, Stauffacher W, Renold AE (1969) Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 48:2129–2139
29. Ganda OP, Rossini AA, Like AA (1976) Studies on streptozotocin diabetes. Diabetes 25:595–603
30. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939–950
31. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52:313–320
32. Lenzen S (2007) Alloxan and streptozotocin diabetes. In: Peschke E (ed) Endokrinologie III Vorträge im Rahmen des Projektes ‘Zeitstrukturen endokriner Systeme’. [Endocrinology III lectures within the ‘time structures of endocrine systems’ project framework]. Abhandlung der Sächs. Akad. Wiss., Mathnaturwiss Klasse, Verlag der Sächsischen Akademie der Wissenschaften, Leipzig, commissioned by S. Hirzel Verlag, Stuttgart/Leipzig, pp 119–138
33. Lenzen S (2008) The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51:216–226
34. Müller D, Nitsch RM, Wurtman RJ, Hoyer S (1998) Streptozotocin increases free fatty acids and decreases phospholipids in rat brain. J Neural Transm 105:1271–1281
35. Masutani M, Suzuki H, Kamada N, Watanabe M, Ueda O, Nozaki T, Jishage K, Watanabe T et al (1999) Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96:2301–2304
36. Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, Verma A, Wang ZQ et al (1999) Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96:3059–3064
37. Cuzzocrea S (2005) Shock, inflammation and PARP. Pharmacol Res 52:72–82
38. King GL, Loeken MR (2004) Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 122:333–338
39. Artola A, Kamal A, Ramakers GM, Biessels GJ, Gispen WH (2005) Diabetes mellitus concomitantly facilitates the induction of long-term depression and inhibits that of long-term potentiation in hippocampus. Eur J Neurosci 22:169–178
40. Beauquis J, Roig P, Homo-Delarche F, De Nicola A, Saravia F (2006) Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment. Eur J Neurosci 23:1539–1546
41. Seyer P, Vallois D, Poitry-Yamate C, Schütz F, Metref S, Tarussio D, Maechler P, Staels B et al (2013) Hepatic glucose sensing is required to preserve β cell glucose competence. J Clin Invest 123:1662–1676
42. Thorens B (2011) Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes Metab 13(Suppl 1):82–88
43. Langlet F, Mullier A, Bouret SG, Prevot V, Dehouck B (2013) Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain. J Comp Neurol 521:3389–3405
44. García M, Millán C, Balmaceda-Aguilera C, Castro T, Pastor P, Montecinos H, Reinicke K, Zúñiga F et al (2003) Hypothalamic ependymal-glial cells express the glucose transporter GLUT2, a protein involved in glucose sensing. J Neurochem 86:709–724
45. Millán C, Martínez F, Cortés-Campos C, Lizama I, Yañez MJ, Llanos P, Reinicke K, Rodríguez F et al (2010) Glial glucokinase expression in adult and post-natal development of the hypothalamic region. ASN Neuro 2:e00035
46. Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J (2009) Intracerebroventricular administration of drugs. Pharmacotherapy 29:832–845
47. Pardridge WM (2011) Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 8:7
48. Woods SC, McKay LD (1978) Intraventricular alloxan eliminates feeding elicited by 2-deoxyglucose. Science 202:1209–1211
49. Ritter S, Murnane JM, Ladenheim EE (1982) Glucoprivic feeding is impaired by lateral or fourth ventricular alloxan injection. Am J Physiol 243:R312–R317
50. Sanders NM, Dunn-Meynell AA, Levin BE (2004) Third ventricular alloxan reversibly impairs glucose counterregulatory responses. Diabetes 53:1230–1236
51. Lanfray D, Arthaud S, Ouellet J, Compère V, Do Rego JL, Leprince J, Lefranc B, Castel H et al (2013) Gliotransmission and brain glucose sensing: critical role of endozepines. Diabetes 62:801–810
52. Lacković Z, Salković M (1990) Streptozotocin and alloxan produce alterations in rat brain monoamines independently of pancreatic beta cells destruction. Life Sci 46:49–54
53. Sapcanin A, Sofic E, Tahirovic I, Salkovic-Petrisic M, Hoyer S, Riederer P (2008) Antioxidant capacity in rat brain after intracerebroventricular treatment with streptozotocin and alloxan—a preliminary study. Neurotox Res 13:97–104
54. Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101:757–770
55. Hoyer S, Müller D, Plaschke K (1994) Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm (Suppl) 44:259–268
56. Salkovic-Petrisic M, Knezovic A, Hoyer S, Riederer P (2013) What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm 120:233–252
57. Hoyer S, Prem L, Sorbi S, Amaducci L (1993) Stimulation of glycolytic key enzymes in cerebral cortex by insulin. Neuroreport 4:991–993
58. Duelli R, Schröck H, Kuschinsky W, Hoyer S (1994) Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci 12:737–743
59. Nitsch R, Hoyer S (1991) Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci Lett 128:199–202
60. Hoyer S, Lee SK, Löffler T, Schliebs R (2000) Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 920:256–258
61. Salkovic-Petrisic M, Osmanovic J, Grünblatt E, Riederer P, Hoyer S (2009) Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J Alzheimers Dis 18:729–750
62. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA (2011) Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev 10:264–273
63. Frisardi V, Solfrizzi V, Capurso C, Imbimbo BP, Vendemiale G, Seripa D, Pilotto A, Panza F (2010) Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? J Alzheimers Dis 21:57–63
64. Anon (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:236-252
65. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW (2000) Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 49:1525–1533
66. Salkovic-Petrisic M, Osmanovic-Barilar J, Brückner MK, Hoyer S, Arendt T, Riederer P (2011) Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J Neural Transm 118:765–772
67. Grieb P, Kryczka T, Fiedorowicz M, Frontczak-Baniewicz M, Walski M (2004) Expansion of the Golgi apparatus in rat cerebral cortex following intracerebroventricular injections of streptozotocin. Acta Neurobiol Exp (Wars) 64:481–489
68. Labak M, Foniok T, Kirk D, Rushforth D, Tomanek B, Jasiński A, Grieb P (2010) Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. Acta Neurochir Suppl 106:177–181
69. Correia SC, Santos RX, Santos MS, Casadesus G, Lamanna JC, Perry G, Smith MA, Moreira PI (2013) Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease. Curr Alzheimer Res 10:406–419
70. Tiwari V, Kuhad A, Bishnoi M, Chopra K (2009) Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. Pharmacol, Biochem Behav 93:183–189
71. Saxena G, Patro IK, Nath C (2011) ICV STZ induced impairment in memory and neuronal mitochondrial function: A protective role of nicotinic receptor. Behav Brain Res 224:50–57
72. Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee MH, Grundke-Iqbal I, Iqbal K et al (2013) A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 47:711–725
73. Rai S, Kamat PK, Nath C, Shukla R (2014) Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats. Pharmacol, Biochem Behav 117:104–117
74. Santos TO, Mazucanti CH, Xavier GF, Torrão AS (2012) Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. Physiol Behav 10:401–413
75. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol 175:2089–2098
76. Chen Y, Liang Z, Tian Z, Blanchard J, Dai CL, Chalbot S, Iqbal K, Liu F et al (2014) intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice. Mol Neurobiol 49:547–462
77. de la Monte SM (2014) Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review. Eur Neuropsychopharmacol 24:1954–1960
78. de la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol 88:548–559
79. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9:13–33
80. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 10:89–109
81. Terwel D, Prickaerts J, Meng F, Jolles J (1995) Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine. Eur J Pharmacol 287:65–71
82. Shoham S, Bejar C, Kovalev E, Weinstock M (2003) Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp Neurol 184:1043–1052
83. Kraska A, Santin MD, Dorieux O, Joseph-Mathurin N, Bourrin E, Petit F, Jan C, Chaigneau M et al (2012) In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin. PLoS One 7:e46196
84. Blondel O, Portha B (1989) Early appearance of in vivo insulin resistance in adult streptozotocin-injected rats. Diabete Metab 15:382–387
85. Kadowaki T, Kasuga M, Akanuma Y, Ezaki O, Takaku F (1984) Decreased autophosphorylation of the insulin receptor-kinase in streptozotocin-diabetic rats. J Biol Chem 259:14208–14216
86. Giorgino F, Chen JH, Smith RJ (1992) Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight nonreceptor protein in vivo in skeletal muscle of streptozotocin-induced diabetic rats: effects of insulin and glucose. Endocrinology 130:1433–1444
87. Reed BC, Lane MD (1980) Insulin receptor synthesis and turnover in differentiating 3 T3-L1 preadipocytes. Proc Natl Acad Sci U S A 77:285–289
88. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J et al (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101:3100–3105
89. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 4:147, ra111
90. Havrankova J, Roth J, Brownstein MJ (1979) Concentrations of insulin and insulin receptors in the brain are independent of peripheral insulin levels. Studies of obese and streptozotocin-treated rodents. J Clin Invest 64:636–642
91. Schechter R, Whitmire J, Holtzclaw L, George M, Harlow R, Devaskar SU (1992) Developmental regulation of insulin in the mammalian central nervous system. Brain Res 582:27–37
92. Banks WA, Owen JB, Erickson MA (2012) Insulin in the brain: there and back again. Pharmacol Ther 136:82–93
93. Schechter R, Beju D, Miller KE (2005) The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun 334:979–986
94. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P (2006) Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem 96:1005–1015
95. Salkovic-Petrisic M, Riederer P (2010) Brain glucose transporter protein 2 and sporadic Alzheimer's disease. Transl Neurosci 1:200–206
96. Arluison M, Quignon M, Nguyen P, Thorens B, Leloup C, Penicaud L (2004) Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain—an immunohistochemical study. J Chem Neuroanat 28:117–136
97. Rodríguez EM, Blázquez JL, Pastor FE, Peláez B, Peña P, Peruzzo B, Amat P (2005) Hypothalamic tanycytes: a key component of brain-endocrine interaction. Int Rev Cytol 247:89–164
98. Coimbra CC, Migliorini RH (1986) Insulin-sensitive glucoreceptors in rat preoptic area that regulate FFA mobilization. Am J Physiol 251:E703–E706
99. Kraegen EW, Cooney GJ (2008) Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 19:235–241
100. Smith QR, Nagura H (2001) Fatty acid uptake and incorporation in brain: studies with the perfusion model. J Mol Neurosci 16:167–172
101. Patil S, Melrose J, Chan C (2007) Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur J Neurosci 26:2131–2141
102. Liu L, Martin R, Kohler G, Chan C (2013) Palmitate induces transcriptional regulation of BACE1 and presenilin by STAT3 in neurons mediated by astrocytes. Exp Neurol 248:482–490
103. de la Monte SM (2012) Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panminerva Med 54:171–178
104. Tong M, Neusner A, Longato L, Lawton M, Wands JR, de la Monte SM (2009) Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis 17:827–844